Virtu Financial LLC Invests $486,000 in Immunome, Inc. (NASDAQ:IMNM)

Virtu Financial LLC purchased a new stake in shares of Immunome, Inc. (NASDAQ:IMNM) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 45,743 shares of the company’s stock, valued at approximately $486,000.

Other institutional investors have also added to or reduced their stakes in the company. AlphaQuest LLC boosted its position in shares of Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock valued at $84,000 after acquiring an additional 7,867 shares during the last quarter. Stoneridge Investment Partners LLC purchased a new stake in shares of Immunome in the fourth quarter valued at $123,000. Teacher Retirement System of Texas purchased a new stake in Immunome in the 4th quarter worth about $124,000. Intech Investment Management LLC raised its holdings in shares of Immunome by 26.5% in the fourth quarter. Intech Investment Management LLC now owns 18,961 shares of the company’s stock worth $201,000 after buying an additional 3,974 shares during the period. Finally, Sequoia Financial Advisors LLC increased its stake in Immunome by 11.7% in the fourth quarter. Sequoia Financial Advisors LLC now owns 19,065 shares of the company’s stock worth $202,000 after purchasing an additional 2,000 shares during the period. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Trading Down 14.7 %

NASDAQ:IMNM opened at $6.95 on Wednesday. Immunome, Inc. has a twelve month low of $6.94 and a twelve month high of $26.70. The company has a market cap of $604.31 million, a PE ratio of -0.86 and a beta of 1.93. The company’s 50 day moving average is $9.67 and its two-hundred day moving average is $11.44.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). The company had revenue of $2.74 million for the quarter, compared to analysts’ expectations of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. As a group, analysts expect that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Insider Activity

In other news, CEO Clay B. Siegall bought 150,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at $5,189,679. This trade represents a 28.87 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Philip Tsai purchased 12,300 shares of the business’s stock in a transaction that occurred on Monday, March 24th. The stock was acquired at an average price of $8.42 per share, for a total transaction of $103,566.00. Following the acquisition, the chief technology officer now owns 33,300 shares in the company, valued at $280,386. This trade represents a 58.57 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 169,300 shares of company stock valued at $1,323,536. Company insiders own 8.60% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on IMNM. Guggenheim decreased their price target on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, March 20th. Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Immunome in a research report on Thursday, March 20th. Stephens restated an “overweight” rating and issued a $30.00 target price on shares of Immunome in a research note on Thursday, March 20th. Finally, Lifesci Capital started coverage on shares of Immunome in a report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $25.50.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.